Senti Biosciences (NASDAQ:SNTI – Get Free Report) and Genelux (NASDAQ:GNLX – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations and institutional ownership.
Valuation and Earnings
This table compares Senti Biosciences and Genelux”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Senti Biosciences | $20,000.00 | 218.05 | -$61.44 million | ($1.77) | -0.08 |
| Genelux | $10,000.00 | 8,459.88 | -$32.15 million | ($0.86) | -2.17 |
Genelux has lower revenue, but higher earnings than Senti Biosciences. Genelux is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
25.7% of Senti Biosciences shares are held by institutional investors. Comparatively, 37.3% of Genelux shares are held by institutional investors. 3.1% of Senti Biosciences shares are held by company insiders. Comparatively, 7.5% of Genelux shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Senti Biosciences and Genelux’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Senti Biosciences | N/A | -1,629.80% | -119.72% |
| Genelux | N/A | -205.85% | -138.79% |
Risk and Volatility
Senti Biosciences has a beta of 2.31, meaning that its stock price is 131% more volatile than the S&P 500. Comparatively, Genelux has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings and target prices for Senti Biosciences and Genelux, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Senti Biosciences | 1 | 0 | 1 | 1 | 2.67 |
| Genelux | 1 | 0 | 2 | 1 | 2.75 |
Senti Biosciences currently has a consensus price target of $9.00, indicating a potential upside of 6,328.57%. Genelux has a consensus price target of $20.00, indicating a potential upside of 969.52%. Given Senti Biosciences’ higher possible upside, equities analysts plainly believe Senti Biosciences is more favorable than Genelux.
Summary
Genelux beats Senti Biosciences on 8 of the 13 factors compared between the two stocks.
About Senti Biosciences
Senti Biosciences, Inc. is a biotechnology company developing gene and cell therapies for cancer and other serious diseases. The company’s technology is based on synthetic biology, including programmable gene circuits designed to help engineered immune cells recognize disease-associated targets, respond to specific biological signals and limit activity in healthy tissue. Senti Biosciences applies its platform to the development of engineered cell therapies, including chimeric antigen receptor natural killer (CAR-NK) and other immune-cell programs.
About Genelux
Genelux Corporation is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer. Its research centers on engineered viruses designed to target and destroy cancer cells while stimulating an immune response against tumors. The company’s lead candidate is olvimulogene nanivacirepvec, also known as Olvi-Vec, an engineered vaccinia virus being studied in clinical trials for ovarian cancer and other solid tumors. Genelux is also advancing additional candidates based on its oncolytic virus platform.
Receive News & Ratings for Senti Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senti Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
